November 6, 2019
“SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced that it filed a certificate of amendment to… Continue Reading…
November 5, 2019
Sellas Life Sciences hit 16 cents in a high today and it may go higher. Every reader who follows me is extremely fortunate. If you take my advice you have a very high chance of making money. I told everyone… Continue Reading…
October 18, 2019
“… The EPS of SELLAS Life Sciences Group, Inc., SLS is strolling at -1.49, measuring its EPS growth this year at 69.8%. As a result, the company has an EPS growth of 64.3% for the approaching year… Target Price informs the investors,… Continue Reading…
September 24, 2019
“The EPS of SLS is strolling at -1.49, measuring its EPS growth this year at 69.8%. As a result, the company has an EPS growth of 64.3% for the approaching year… Analyst’s mean target price for the company is $1.75 while analysts… Continue Reading…
Recent Comments